The PPI network predicted key targets of the main active components of JDXLF for treating DLBCL, including AKT1, TP53, CASP3 JUN, epidermal growth factor receptor (EGFR), and MYC. This evidence concerns the gene MYC and diffuse large B-cell lymphoma.